Literature DB >> 7693415

Anthracyclines in the treatment of early breast cancer.

H T Mouridsen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7693415     DOI： 10.2165/00003495-199300452-00002

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  13 in total

Review 1.  Systemic therapy of advanced breast cancer.

Authors:  H T Mouridsen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

2.  Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.

Authors:  B Fisher; A M Brown; N V Dimitrov; R Poisson; C Redmond; R G Margolese; D Bowman; N Wolmark; D L Wickerham; C G Kardinal
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

3.  A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study.

Authors:  D C Tormey; V E Weinberg; L A Leone; O J Glidewell; M Perloff; B J Kennedy; E Cortes; R T Silver; R B Weiss; J Aisner
Journal:  Am J Clin Oncol       Date:  1984-06       Impact factor: 2.339

Review 4.  Present status of anthracyclines in the adjuvant treatment of breast cancer.

Authors:  G N Hortobágyi; A U Buzdar
Journal:  Drugs       Date:  1993       Impact factor: 9.546

5.  The Canadian experience with intensive fluorouracil, epirubicin and cyclophosphamide in patients with early stage breast cancer.

Authors:  M N Levine; V Bramwell; K Pritchard; D Perrault; B Findlay; H Abu-Zahra; D Warr; A Arnold; J Skillings
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 6.  Anthracyclines in the adjuvant treatment of breast cancer.

Authors:  M Namer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.

Authors:  J Aisner; V Weinberg; M Perloff; R Weiss; M Perry; A Korzun; S Ginsberg; J F Holland
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

8.  Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.

Authors:  H B Muss; D R White; F Richards; M R Cooper; J J Stuart; D V Jackson; L Rhyne; C L Spurr
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

Review 9.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

10.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-11       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.